Total submissions: 5
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Biesecker Lab/Clinical Genomics Section, |
RCV000172323 | SCV000054993 | uncertain significance | not provided | 2013-06-24 | criteria provided, single submitter | research | |
CHEO Genetics Diagnostic Laboratory, |
RCV001170840 | SCV001333460 | uncertain significance | Cardiomyopathy | 2017-11-30 | criteria provided, single submitter | clinical testing | |
Women's Health and Genetics/Laboratory Corporation of America, |
RCV001269253 | SCV001448576 | uncertain significance | not specified | 2020-11-02 | criteria provided, single submitter | clinical testing | Variant summary: TTN c.40414C>T (p.Arg13472Cys) results in a non-conservative amino acid change located in the A- band region (cardiodb.org) of the encoded protein sequence. Four of five in-silico tools predict a benign effect of the variant on protein function. The variant allele was found at a frequency of 2e-05 in 247604 control chromosomes. The available data on variant occurrences in the general population are insufficient to allow any conclusion about variant significance. To our knowledge, no occurrence of c.40414C>T in individuals affected with Dilated Cardiomyopathy and no experimental evidence demonstrating its impact on protein function have been reported. One clinical diagnostic laboratory has submitted clinical-significance assessments for this variant to ClinVar after 2014 without evidence for independent evaluation, citing the variant as uncertain significance. Based on the evidence outlined above, the variant was classified as uncertain significance. |
Mayo Clinic Laboratories, |
RCV000172323 | SCV002541949 | uncertain significance | not provided | 2021-12-06 | criteria provided, single submitter | clinical testing | |
Revvity Omics, |
RCV000172323 | SCV003819835 | uncertain significance | not provided | 2021-03-08 | criteria provided, single submitter | clinical testing |